3-(3-甲基-1H-吡唑-1-基)丙酸 | 72145-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(3-甲基-1H-吡唑-1-基)丙酸
• 英文名称: 3-(3-methyl-1H-pyrazol-1-yl)propanoic acid
• 英文别名: 3-(3-methyl-pyrazol-1-yl)propanoic acid；3-(3-methyl-pyrazol-1-yl)propionic acid；3-(3-methylpyrazol-1-yl)propanoic acid
• CAS: 72145-00-7
• 化学式: C₇H₁₀N₂O₂
• mdl: MFCD00577274
• 分子量: 154.169
• InChiKey: FPLLCFQUZAEVIE-UHFFFAOYSA-N

物化性质

• 溶解度：
  7.9 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933199090
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  3-(3-甲基-1H-吡唑-1-基)丙酸 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 3-(3-methylpyrazol-1-yl)propanoyl azide
  参考文献：
  名称：

  2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924

  摘要：

  A series of IGF-1R inhibitors is disclosed, wherein the (m-chlorophenyl) ethanol side chain of BMS-536924 (1) is replaced with a series of 2-(1H-imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chains. Some analogs show improved IGF-1R potency and oral exposure. Analogs from both series, 16a and 17f, show in vivo activity comparable to 1 in our constitutively activated IGF-1R Sal tumor model. This may be the due to the improved protein binding in human and mouse serum for imidazole 16a and the excellent oral exposure of pyrazole 17f. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.049

文献信息

• MCL-1 INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20190352271A1

  公开（公告）日：2019-11-21

  The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

  本公开涉及通常用于治疗癌症的化合物和药物组合物。
• CYCLIC AMINE DERIVATIVE AND MEDICAL USE THEREOF
  申请人：Toray Industries, Inc.

  公开号：US20180370916A1

  公开（公告）日：2018-12-27

  A compound has retinoid-related orphan receptor γ antagonist activity and shows a therapeutic effect or a preventive effect on autoimmune diseases such as multiple sclerosis or psoriasis or allergic diseases, including allergic dermatitis or the like, such as contact dermatitis or atopic dermatitis. The cyclic amine derivative is represented by the formula or a pharmacologically acceptable salt thereof.

  一种化合物具有类视黄醇相关孤儿受体γ拮抗活性，并对自身免疫性疾病如多发性硬化或牛皮癣或过敏性疾病，包括过敏性皮炎等，如接触性皮炎或特应性皮炎等，显示治疗效果或预防效果。该环胺衍生物由以下公式或其药理学可接受的盐表示。
• Piperazines as P2X7 antagonists
  申请人：Betschmann Patrick

  公开号：US20080076924A1

  公开（公告）日：2008-03-27

  Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

  化合物I式的新型化合物或其药学上可接受的盐、代谢物、异构体、对映体或前药，其中取代基如本文所定义，这些化合物可用作治疗剂。
• Inhibitors of phosphatidylinositol 3-kinase
  申请人：Bruce Ian

  公开号：US20070032487A1

  公开（公告）日：2007-02-08

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  公式I的化合物以自由或盐形式存在，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的制药组合物以及制备这些化合物的过程。
• INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：BRUCE Ian

  公开号：US20110105535A1

  公开（公告）日：2011-05-05

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  式I的化合物，无论是自由形式还是盐形式，其中R1、R2、R3和R4的含义如说明书所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的制药组合物以及制备这些化合物的过程。